Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This is a single-arm，open-label study to evaluate the efficacy and safety of tislelizumab
plus chemotherapy for conversion therapy of patients with locally nonresectable ESCC.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University